Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma
Biomedical Genetics and Genomics · 2016
DOI: 10.15761/bgg.1000116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Genetics and Genomics, 2016. Verfasst von Minal Barve und 9 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Barve, M., Kuhn, J., Lamont, J., Beitsch, P., Manning, L., Pappen, B. O., Kumar, P., Wallraven, G., Senzer, N., & Nemunaitis, J. (2016). Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma. Biomedical Genetics and Genomics. https://doi.org/10.15761/bgg.1000116
Vancouver
Barve M, Kuhn J, Lamont J, Beitsch P, Manning L, Pappen BO, et al. Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma. Biomedical Genetics and Genomics. 2016. doi:10.15761/bgg.1000116
BibTeX
@article{Barve2016,
author = {Barve, Minal and Kuhn, Joseph and Lamont, Jeffrey and Beitsch, Peter and Manning, Luisa and Pappen, Beena O. and Kumar, Padmasini and Wallraven, Gladice and Senzer, Neil and Nemunaitis, John},
title = {Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma},
journal = {Biomedical Genetics and Genomics},
year = {2016},
doi = {10.15761/bgg.1000116}
}
EUVIMED